166438-83-1 Usage
General Description
(1-(4-Nitrophenyl)piperidin-3-yl)Methanol is a chemical compound with a long, complex name. It is a piperidine derivative with a substituent containing a nitrophenyl group and a methanol group. (1-(4-Nitrophenyl)piperidin-3-yl)Methanol may have potential applications in pharmaceutical research and development as it could be used as a building block for the synthesis of other organic molecules. The presence of the methyl and nitrophenyl groups may also confer specific properties or reactivity to the compound, making it potentially useful in various chemical reactions or as a starting material for the production of specific pharmaceuticals or other industrial products. However, as with any chemical compound, the use and handling of (1-(4-Nitrophenyl)piperidin-3-yl)Methanol should be done with care and in accordance with appropriate safety guidelines and regulations.
Check Digit Verification of cas no
The CAS Registry Mumber 166438-83-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,6,4,3 and 8 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 166438-83:
(8*1)+(7*6)+(6*6)+(5*4)+(4*3)+(3*8)+(2*8)+(1*3)=161
161 % 10 = 1
So 166438-83-1 is a valid CAS Registry Number.
166438-83-1Relevant articles and documents
COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS
-
Page/Page column 100, (2015/03/28)
The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.